Vertaling van "al mortality " (Frans → Nederlands) :

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

To asses the effects of poorer outcomes, we added the peri-procedural mortality of low volume centres in the US, using the observed risk ratio of death to the risks of stroke or death; low volume centres showed a 1.8 times higher peri-procedural mortality. 50
To asses the effects of poorer outcomes, we added the peri-procedural mortality of low volume centres in the US, using the observed risk ratio of death to the risks of stroke or death; low volume centres showed a 1.8 times higher peri-procedural mortality.[50]

The graphs „Medical treatment‰ and „trial centres‰ show the results of the ACST/ACAS trials (expressed as constant hazards of stroke or death from the trials and age dependent hazards of all other cause mortality from the Flemish male life table at age 70 in the year 2000). 18 Intervention starts with a short period of high (peri-procedural) mortality, but the lower post-procedural hazard of death will overtake the higher hazard of medical treatment.
The graphs „Medical treatment‰ and „trial centres‰ show the results of the ACST/ACAS trials (expressed as constant hazards of stroke or death from the trials and age dependent hazards of all other cause mortality from the Flemish male life table at age 70 in the year 2000).[18] Intervention starts with a short period of high (peri-procedural) mortality, but the lower post-procedural hazard of death will overtake the higher hazard of medical treatment.

FA + iron (60 mg), FA + iron + or without zinc (30 mg), or multiple iron) or micronutrients (MNs; the iron + zinc foregoing plus 10 microg vitamin had a D, 10 mg vitamin E, 1.6 mg consistent thiamine, 1.8 mg riboflavin, 2.2 mg pattern of vitamin B-6, 2.6 microg vitamin B- 15-20% 12, 100 mg vitamin C, 64 microg lower 3-mo vitamin K, 20 mg niacin, 2 mg Cu, mortality; and 100 mg Mg).
zinc (30 mg), or multiple iron) or micronutrients (MNs; the iron + zinc foregoing plus 10 microg vitamin had a D, 10 mg vitamin E, 1.6 mg consistent thiamine, 1.8 mg riboflavin, 2.2 mg pattern of vitamin B-6, 2.6 microg vitamin B- 15-20% 12, 100 mg vitamin C, 64 microg lower 3-mo vitamin K, 20 mg niacin, 2 mg Cu, mortality; and 100 mg Mg).

Brusselaers N, Monstrey S, Vogelaers D, Hoste E, Blot S. Severe burn injury in Europe: a systematic review of the incidence, etiology, morbidity, and mortality.
12. Jennes S, Casaer, M., Colpaert, K., Magnette, A. Aanbevelingen van de BABI: Pre- en intrahospitaal management van zwaar verbranden buiten een brandwondencentrum tijdens de eerste 72 uren na de verbranding. In: Belgian Association for Burn Injuries; 2007.

Table 9: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 7: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence

Angst F., Stassen H.H., Clayton, P.J., Angst, J. Mortality of patients with Mood Disorders: Follow-up over 34-38 years.
Angst F., Stassen H.H., Clayton, P.J., Angst, J. Mortality of patients with Mood Disorders: Followup over 34-38 years.

Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis Morbidity and Mortality Weekly Report Recommendations and Reports MMWR 2005 ; 54(RR9).1-17.
Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis Morbidity and Mortality Weekly Report Recommendations and Reports MMWR 2005; 54(RR9).1-17.

D’après K. Dickstein et al.: Effects of losartan and captopril on mortality and morbidity in highrisk patients after acute myocardial infarction: the OPTIMAAL randomised trial.
Naar K. Dickstein et al.: Effects of losartan and captopril on mortality and morbidity in highrisk patients after acute myocardial infarction: the OPTIMAAL randomised trial.

Table 12: Overall mortality reduction for woman between 40-49y (KCE table)
Table 10: Overall mortality reduction for woman between 40-49y (KCE table)